102 related articles for article (PubMed ID: 23766520)
1. Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes.
de Souza GF; Barbosa MC; Santos TE; Carvalho TM; de Freitas RM; Martins MR; Gonçalves RP; Pinheiro RF; Magalhães SM
J Clin Pathol; 2013 Nov; 66(11):996-8. PubMed ID: 23766520
[No Abstract] [Full Text] [Related]
2. Plasma levels of aminothiols, nitrite, nitrate, and malondialdehyde in myelodysplastic syndromes in the context of clinical outcomes and as a consequence of iron overload.
Pimková K; Chrastinová L; Suttnar J; Štikarová J; Kotlín R; Čermák J; Dyr JE
Oxid Med Cell Longev; 2014; 2014():416028. PubMed ID: 24669287
[TBL] [Abstract][Full Text] [Related]
3. The role of iron overload on oxidative stress in sickle cell anemia.
Dos Santos TE; de Sousa GF; Barbosa MC; Gonçalves RP
Biomark Med; 2012 Dec; 6(6):813-9. PubMed ID: 23227847
[TBL] [Abstract][Full Text] [Related]
4. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique.
Konen E; Ghoti H; Goitein O; Winder A; Kushnir T; Eshet Y; Rachmilewitz E
Am J Hematol; 2007 Nov; 82(11):1013-6. PubMed ID: 17654681
[TBL] [Abstract][Full Text] [Related]
5. Iron overload in MDS-pathophysiology, diagnosis, and complications.
Gattermann N; Rachmilewitz EA
Ann Hematol; 2011 Jan; 90(1):1-10. PubMed ID: 20938663
[TBL] [Abstract][Full Text] [Related]
6. Peroxidative stress and antioxidant enzymes in children with beta-thalassemia major.
Naithani R; Chandra J; Bhattacharjee J; Verma P; Narayan S
Pediatr Blood Cancer; 2006 Jun; 46(7):780-5. PubMed ID: 16317757
[TBL] [Abstract][Full Text] [Related]
7. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
[TBL] [Abstract][Full Text] [Related]
8. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
Dreyfus F
Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
[TBL] [Abstract][Full Text] [Related]
9. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
[TBL] [Abstract][Full Text] [Related]
10. Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients.
Pascal L; Beyne-Rauzy O; Brechignac S; Marechaux S; Vassilieff D; Ernst O; Berthon C; Gyan E; Gourin MP; Dreyfus F; Fenaux P; Rose C
Br J Haematol; 2013 Aug; 162(3):413-5. PubMed ID: 23656172
[No Abstract] [Full Text] [Related]
11. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
12. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.
Hartmann J; Braulke F; Sinzig U; Wulf G; Maas JH; Konietschke F; Haase D
Leuk Res; 2013 Mar; 37(3):327-32. PubMed ID: 23259989
[TBL] [Abstract][Full Text] [Related]
13. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines.
Mittelman M; Lugassy G; Merkel D; Tamary H; Sarid N; Rachmilewitz E; Hershko C; ;
Isr Med Assoc J; 2008 May; 10(5):374-6. PubMed ID: 18605364
[No Abstract] [Full Text] [Related]
14. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
Gattermann N; Finelli C; Porta MD; Fenaux P; Ganser A; Guerci-Bresler A; Schmid M; Taylor K; Vassilieff D; Habr D; Domokos G; Roubert B; Rose C;
Leuk Res; 2010 Sep; 34(9):1143-50. PubMed ID: 20451251
[TBL] [Abstract][Full Text] [Related]
15. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
Wells RA; Leber B; Buckstein R; Lipton JH; Hasegawa W; Grewal K; Yee K; Olney HJ; Larratt L; Vickars L; Tinmouth A
Leuk Res; 2008 Sep; 32(9):1338-53. PubMed ID: 18405971
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of deferasirox in myelodysplastic syndromes.
Breccia M; Alimena G
Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
[TBL] [Abstract][Full Text] [Related]
18. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
19. Iron overload, cardiac iron loading and function in myelodysplastic syndrome.
Angelucci E; Di Tucci AA
Leuk Res; 2009 Jun; 33(6):743-4. PubMed ID: 19195702
[No Abstract] [Full Text] [Related]
20. [Detection of Hepcidin in transfusion dependent myelodysplastic syndrome patients and its clinical significance].
Qin Y; Liu H; Ruan S; Cai YF; You XF; Song GQ
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):758-61. PubMed ID: 22339912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
